$110B market: excessive spending on me-too PD-1 drugs?

Regulator says too many drugmakers chasing same cancer strategy   Reuters reports that Dr. Richard Pazdur, who heads the Food and Drug Administration’s office of oncology products, believes that?too many companies are focused on PD-1 inhibitors for?cancer immunotherapy. Whereas PD-1 inhibitors show promise for remarkable efficacy, Dr. Pazdur is reportedly concerned that?too many companies are[…]

Biosimilar switching: new evidence against interchangeability

Biosimilar Switching Not Suitable For All Patients 100% of patients?who developed antibodies to?innovator anti-TNF-? exhibited antibody reactivity against the biosimilar. ?Study results cast?doubt on interchangeability. 8 June 2016 According to a report from European League Against Rheumatism Annual Congress (EULAR) 2016, patients with antibodies to biological infliximab are less likely to benefit from infliximab biosimilar[…]